Seizert Capital Partners’s ResMed RMD Stock Holding History

Seizert Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-6,300	Closed	-$319K	–	216
2014 Q2	$319K	Hold	6,300	–	–	0.01%	175
2014 Q1	$282K	Hold	6,300	–	–	0.01%	181
2013 Q4	$297K	Hold	6,300	–	–	0.01%	177
2013 Q3	$333K	Sell	6,300 -500	-7%	-$24.3K	0.01%	166
2013 Q2	$307K	Buy	+6,800	New	+$323K	0.01%	170

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Seizert Capital Partners's RMD Position: Q3 2014 in Review

Seizert Capital Partners sold out of ResMed (RMD) in Q3 2014, closing a stake of 6,300 shares — an estimated $319K sold.

Seizert Capital Partners first reported a position in RMD in Q2 2013 and held it in 5 quarters. The position peaked at $333K in Q3 2013. 300 funds tracked by Wall St. Rank hold RMD as of Q3 2014.

Seizert Capital Partners reported no remaining ResMed position as of Q3 2014 after selling out during the quarter.
Seizert Capital Partners sold 6,300 ResMed shares in Q3 2014, an estimated $319K.
Seizert Capital Partners first reported a position in ResMed in Q2 2013 and held it in 5 quarters.
Seizert Capital Partners's ResMed position peaked at $333K in Q3 2013.
300 funds tracked by Wall St. Rank held ResMed as of Q3 2014.

Based on Seizert Capital Partners's 13F filing for Q3 2014, filed 6 Nov 2014.